Podcast + Q&A: Device-Makers Shouldn't Ignore Pharma Quality Metrics Initiative, Attorney Says
This article was originally published in The Gray Sheet
In a Dec. 9 podcast interview at the Food and Drug Law Institute Enforcement, Litigation and Compliance meeting in Washington, D.C., Alston & Bird partner Cathy Burgess discussed how the FDA’s quality metrics initiative for pharmaceutical companies may also impact expectations for device manufacturers down the line.
You may also be interested in...
The Mallorca-based biotech is building a strong data package for SNF472 which the company believes will be an effective treatment for a number of calcification disorders in dialysis patients.
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.